ATHE 6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of September 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073,333-248980 and 333-228671)and our Registration Statements on Form F-3 (Files No. 333-274816,333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Notice Under Section 708A |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: September 15, 2025
2
Exhibit 99.1
| ASX ANNOUNCEMENT | 15 September 2025 |
|---|
Notice Under Section 708A(5)(e) of the CorporationsAct
This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).
| Details of securities issued | |
|---|---|
| Type: | Shares |
| Class/Description: | Fully paid ordinary shares |
| ASX Code: | ATH |
| Date of Issue: | 15 September 2025 |
| Number Issued: | 1,666,666,663 |
The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act that:
| 1. | the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; |
|---|---|
| 2. | as at the date of this notice, the Company has complied with: |
| --- | --- |
| (i) | the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and |
| --- | --- |
| (ii) | sections 674 and 674A of the Corporations Act; and |
| --- | --- |
| 3. | as at the date of this notice there is no information to be disclosed which is ‘excluded information’<br>(as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company. |
| --- | --- |
Abby Macnish Niven
Company Secretary
Alterity Therapeutics Limited ACN 080 699 065
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
www.alteritytherapeutics.com